T cell receptor gamma variable A (pseudogene)Genealiases: TCRGVA · V5P
Q-omics provides the consensus-scored TRGVA profile across patient tissues and cancer cell-line models. TRGVA expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, TRGVA is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, TRGVA RNA expression shows 7,517 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight STAD, KIRC, and UVM as cancer lineages where TRGVA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRGVA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRGVA survival associations across molecular data types. TRGVA RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRGVA RNA expression–survival associations across cancer types. High TRGVA expression shows unfavorable associations in STAD, UCS, DLBC and KIRP, but favorable associations in ESCA and BLCA. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify STAD as the clearest survival context for TRGVA RNA expression.
This table summarizes TRGVA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRGVA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRGVA shows lower tumor expression in LUAD and LUSC and higher tumor expression in KIRC and PRAD. The KIRC box plot shows higher TRGVA RNA expression in tumor versus normal tissue (log2 FC = +0.236, t-test p < 0.001).
This table shows molecular features associated with TRGVA in patient tissues and cancer cell lines. In patient samples, TRGVA shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
